Whitehawk Data Validates MUC16 as Top ADC Target in Gynecologic Cancers

Event summary

  • Whitehawk presented real-world data at SGO 2026 confirming MUC16 as the highest-expressing ADC target in ovarian cancer, with 2- to >100-fold higher expression than competitors.
  • MUC16 shows stable expression across aggressive endometrial cancer subtypes, including serous adenocarcinoma (40% of deaths) and endometrioid adenocarcinoma (90% of cases).
  • HWK-016, Whitehawk's next-gen MUC16-targeted ADC, is in Phase 1 trials (NCT07470853) with initial data expected in H1 2027.
  • The analysis was conducted via collaboration with Tempus AI, leveraging large-scale RNA data.

The big picture

Whitehawk's data reinforces the strategic shift toward next-generation ADCs with improved tumor selectivity and payload delivery. The stable expression of MUC16 across aggressive cancer subtypes positions HWK-016 as a potential frontline treatment, though competition in the ADC space remains intense. The collaboration with Tempus AI highlights the growing role of AI-driven real-world data in validating oncology targets.

What we're watching

Clinical Validation
Whether HWK-016 can demonstrate superior efficacy by targeting the membrane-bound portion of MUC16, avoiding the antigen sink effect of earlier ADCs.
Market Differentiation
How Whitehawk positions HWK-016 against competitors targeting other ADC markers like NaPi2b, HER2, and TROP2 in ovarian and endometrial cancers.
Regulatory Pathway
The pace at which Whitehawk advances HWK-016 through Phase 1 and potential accelerated approval pathways given the high unmet need in gynecologic cancers.

Related topics

Biotechnology Oncology